Epizyme falls on DLBCL discontinuations for tazemetostat
Epizyme Inc. (NASDAQ:EPZM) lost $3.10 (24%) to $9.90 on Aug. 2 after discontinuing development of tazemetostat both as monotherapy and in combination with prednisolone to treat diffuse large B cell lymphoma (DLBCL). The news comes three months after FDA placed a partial hold on tazemetostat, Epizyme's most advanced candidate, suspending new enrollment in U.S. clinical trials.
In its 2Q18 earnings, Epizyme said an interim analysis of patients with relapsed and/or refractory DLBCL in the Phase II portion of a Phase I/II trial showed that the clinical activity of tazemetostat as monotherapy and in combination with prednisolone was insufficient to warrant further development. The company plans to present data at a medical meeting this half...
BCIQ Target Profiles